Abstract
HBV is a double-stranded, enveloped virus of the Hepadnaviridae family. The Hepadna virus family has the smallest genome of all replication competent animal DNA viruses. The single most important member of the family is HBV. Eight genotypes of HBV have been identified; they have been termed A-H. These genotypes are associated with a particular geographic distribution: genotype A being most common in the United States and Northern Europe, B and C in Asia, and D in Mediterranean countries and the Middle East (Table ). he association of HBV genotypes with different clinical outcome and response to interferon has been described: chronic infection with genotype B appears to have a better prognosis than genotype C. Pre-core mutant infection is also most common in genotypes B, C and D, which explains why pre-core mutant infection is more common in Asia and Southern Europe. Further research is currently being performed on the role of these genotypes in transmission, disease pattern, and response to therapy
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Banatvala, J.E., & Van Damme, P. (2003). Hepatitis B vaccine-do we need boosters? J Hepatol, (10), 1–6.
Banatvala, J.E., Van Damme, P., & Emiroglu, N. (2006). Hepatitis B immunization in Britain: time to change? BMJ, (332), 804–805.
Bonanni, P., Pesavento, G., Bechini, A., Tiscione, E., Mannelli, F., Benucci, C., & Nostro, A.L. (2003). Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine, (21), 685–691.
Centers for Disease Control and Prevention 1987 (1987). Recommendations of the immunization practices advisory committee. Update on hepatitis B prevention. Morbid Mortal Weekly Report, (36), 353–360.
Chan, C.Y., Lee, S.D., & Lo, K.J. (2004). Legend of hepatitis B vaccination: the Taiwanese experience. J Gastroenterol Hepatol, (19), 121–126.
Chen, C.-J., Yang, H.-I., Su, J., Jen, C.-L., You, S.-L., Lu, S.-N., Huang, G.-T. et al. (2006). Risk of HCC across a biological gradient of serum HBV-DNA levels. JAMA, (295), 65–73.
Coursaget, P., Leboulleux, D., Soumare, M., le Cann, P., Yvonnet, B., Chiron, J.P. et al. (1994). Twelve-year follow-up study of hepatitis B immunisation of Senegalese infants. J Hepatol, (21), 250–254.
Da Villa, G., Romanò, L., Sepe, A., Iorio, R., Parimbello, N., Zappa, A., & Zanetti, A.R. (2007). Impact of hepatitis B vaccination in high endemic area of south Italy and long-term duration of anti-HBs antibody in two cohort of vaccinated individuals. Vaccine, (25), 3133–3136.
Dienstag, J.L., Werner, B.G., Polk, B.F., Snydman, D.R., Craven, D.E., & Platt, R. (1984). Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med, (82), 8168–8172.
Duclos, P. (2003). Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol, (39), 83–88.
EUROHEP.NET (2004). Data on surveillance and prevention of hepatitis A and B in 22 countries, 1990–2001. Antwerp; (also available on http://www.eurohep.net)
European Consensus Group on Hepatitis B immunity (2000). Are booster immunisations needed for lifelong hepatitis B immunity? Lancet, (355), 561–565.
Erhardt, A., Blondin, D., Hauck, K., Sagir, A., Kohnle, T., Heintges, T., & Häussinger, D. (2005). Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut, (54), 1009–1013.
Francois, G., Hallauer, J., & Van Damme, P. (2002). Hepatitis B vaccination: how to reach risk groups. Vaccine, (21), 1–4.
Gaeta, G.B., Stroffolini, T., Chiaramonte, M., Ascione, T., Stornaiuolo, G., Lobello, S., Sagnelli, E. et al. (2000). Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology, (32), 824–827.
Goldstein, S.T., Zhou, F., Hadler, S.C., Bell, B.P., Mast, E.E., & Margolis, H.S. (2005). A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol, (34), 1329–1339. Available at: http://aim.path.org/en/vaccines/hepb/assessBurden/model/index.html (retrieved on 3 October 2008).
Hadler, S.C. & Margolis, H.S. (1992). Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Topics In Infectious Diseases. J.S. Remington, & M.N. Swartz (Eds.). (Vol. 12). Boston: Blackwell Scientific Publications, pp. 282–308.
Hahné, S., Ramsay, M., Balogun, K., Edmunds, W.J., & Mortimer, P. (2004). Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: implications for immunisation policy. J Clin Virol, (29), 211–220.
Hollinger, F.B. (1989). Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med, 87(Suppl 3A), 36–40.
Jilg, W., Schmidt, M., Zachoval, R., & Deinhardt, F. (1984). Hepatitis B vaccination: how long does protection last? Lancet, (2), 458.
Jilg, W., Schmidt, M., & Deinhardt, F. (1988). Persistence of specific antibodies after hepatitis B vaccination. J Hepatol, (6), 201–207.
Kao, J.-H. & Chen, D.S. (2005). Hepatitis B vaccination: to boost or not to boost? Lancet, (366), 1337–1338.
Keating, G.M. & Noble, S. (2003). Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs, (63), 1021–1051.
Kretzschmar, M. & de Wit, A. (2008). Universal hepatitis B vaccination. Lancet, (8), 85–87.
Lavanchy, D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, (11), 97–107.
Lavanchy, D. (2005). Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol, 34(Suppl 1), 1–3.
Lok, A.S.F. & McMahon, B.J. (2007). Chronic hepatitis B: AASLD practice guidelines. Hepatology, (45), 507–539.
Mahoney, F.J. (1999). Update on diagnosis, management and prevention of hepatitis B virus infection. Clin Microbiol Rev, (12), 351–366.
Ng, K.P., Saw, T.L., Baki, A., Rozainah, K., Pang, K.W., & Ramanathan, M. (2005). Impact of expanded programme on immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol, (194), 163–168.
Niu, M.T. (1996). Review of 12 million doses shows hepatitis B vaccine safe. Vaccine Weekly, (4), 13–15.
Perz, J.F., Elm, J.L., Jr., Fiore, A.E., Huggler, J.I., Kuhnert, W.L., & Effler, P.V. (2006). Near elimination of hepatitis B infections among Hawaii elementary school children universal infant hepatitis B vaccination. Pediatrics, (118), 1403–1408.
Piazza, M., Da Villa, G., Picciotto, L., Abrescia, N., Guadagnino, V., Memoli, A.M., Vegnente, A. et al. (1988). Mass vaccination against hepatitis B in infants in Italy. Lancet, (332), 1132.
Pollard, A.J. (2007). Hepatitis B vaccination. BMJ, (335), 950.
Rendi-Wagner, P., Shouval, D., Genton, B., Lurie, Y., Rumke, H., Boland, G., Cerny, A. et al. (2006). Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine, (24), 2781–2789.
Romanò, L., Mele, A., Pariani, E., Zappa, A., & Zanetti, A. (2004). Update in the universal vaccination against hepatitis B in Italy: 12 years after its implementation. Eur J Public Health, 14(Suppl), S19.
Safary, A. & André, F. (1999). Over a decade of experience with the yeast recombinant hepatitis B vaccine. Vaccine, (18), 57–67.
Shaefer, S. (2005). Hepatitis B virus: significance of genotypes. J Viral Hepat, (12), 111–124.
Shepard, E.W., Simard, E.P., Finelli, L., Fiore, A.E., & Bell, B.P. (2006). Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev, (28), 112–125.
Sherlock, S. (1993). Clinical features of hepatitis. In: Viral Hepatitis. A.J. Zuckerman, H.S. Thomas (Eds.). London: Churchill Livingstone, pp. 1–11.
Shouval, D., Ilan, Y., Adler, R., Deepen, R., Panet, A., Even-Chen, Z., Gorecki, M. et al. (1994). Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine, (12), 1453–1459.
Szmuness, W., Stevens, C.E., Zang, E.A., Harley, E.J., & Kneller, A. (1981). A controlled clinical trial of the efficacy of the hepatitis B vaccine (Hepatavax B): a final report. Hepatology, (5), 377–385.
Tan, J. & Lok, A.S.F. (2007). Update on viral hepatitis: 2006. Gastroenterology, (23), 263–267.
Tandon, B.N. & Tandon, A. (1997). Epidemiological trends of viral hepatitis in Asia. In: Viral Hepatitis and Liver Disease. M. Rizzetto, R.H. Purcell, J.L. Gerin, & G. Verme (Eds.). Turin: Edizioni Minerva Medica, pp. 559–661.
Tilson, L., Thornton, L., O’Flanagan, D., Johnson, H., & Barry, M. (2008). Cost-effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health, 18(3), 275–282.
Van Damme, P., Kane, M., & Meheus, A. (1997). Integration of hepatitis B vaccination into national immunisation programmes. BMJ, (314), 1033–1037.
Van Damme, P., Van Herck, K., Leuridan, E., & Vorsters, A. (2004). Introducing universal hepatitis B vaccination in Europe: differences still remain between countries. Eurosurveillance Weekly, (9), 67–68.
Van Damme, P. & Van Herck, K. (2007). A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis, (5), 79–84.
van der Eijk, A.A., Niesters, H.G.M., Götz, H.M., Janssen, H.L.A., Schalm, S.W., Osterhaus, A.D.M.E., & de Man, R.A. (2004). Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. J Clin Virol, (29), 92–94.
van Houdt, R., Sonder, G.J., Dukers, N.H., Bovee, L.P., van den Hoek, A., Coutinho, R.A., & Bruisten, S.M. (2007). Impact of targeted hepatitis B vaccination program in Amsterdam, the Netherlands. Vaccine, (25), 2698–2705.
Venters, C., Graham, W., & Cassidy, W. (2004). Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines, (3), 119–129.
Viviani, S., Jack, A., Hall, A.J., Maine, N., Mendy, M., Montesano, R., & Whittle, H.C. (1999). Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine, (17), 2946–2950.
Wainwright, R., Bulkow, L.R., Parkinson, A.J., Zanis, C., & McMahon, B.J. (1997). Protection provided by hepatitis B vaccine in a Yupik Eskimo Population: results of a 10 year study. J Infect Dis, (175), 674–677.
West, D.J. & Calandra, G.B. (1996). Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine, (14), 1019–1027.
Whittle, H.C., Maine, N., Pilkington, J., Mendy, M., Fortuin, M., Bunn, J., Allison, L. et al. (1995). Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet, (345), 1089–1092.
World Health Organization 1992. (1992). Informal consultation on quadrivalent diphtheria-tetanus-pertussis-hepatitis B vaccine. Final Report, pp.1–12, Geneva.
World Health Organization (2004). Hepatitis B vaccines (WHO position paper). Weekly Epidemiol Record, (79), 255–263.
World Health Organization 2006. Vaccines and biologicals. WHO vaccine preventable disease monitoring system. Global summary 2006 (data up to 2005). Available at http://www.who.int/vaccines-documents/GlobalSummary.pdf (retrieved on 15 September 2007).
Zanetti, A.R., Tanzi, E., Romanò, L., & Grappasonni, I. (1993). Vaccination against hepatitis B: the Italian strategy. Vaccine, (11), 521–524.
Zanetti, A.R., Mariano, A., Romanò, L., D’Amelio, R., Chironna, M., Coppola, R.C., Cuccia, M., Mangione, R., Marrone, F., Negrone, F.S., Parlato, A., Zamparo, E., Zotti, C., Stroffolini, T., & Mele, A; Study Group. (2005). Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet, 366(9494), 1379–1384.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Van Damme, P., Zanetti, A.R., Shouval, D., Van Herck, K. (2010). Strategies for Global Prevention of Hepatitis B Virus Infection. In: Finn, A., Curtis, N., Pollard, A. (eds) Hot Topics in Infection and Immunity in Children VI. Advances in Experimental Medicine and Biology, vol 659. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0981-7_14
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0981-7_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0980-0
Online ISBN: 978-1-4419-0981-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)